Doctors with M Health Fairview Masonic Children’s Hospital are experts in the treatment of neuroblastoma. This gives our team a rare understanding of this uncommon cancer. In fact, M Health Fairview Masonic Children’s Hospital is the only facility in Minnesota able to offer targeted therapy using radioiodine-labeled metaiodobenzylguanidine (I131-MIBG) for children with recurrent or difficult-to-treat neuroblastomas.
In addition, the University of Minnesota houses the only National Cancer Institute-funded Children’s Oncology Group phase 1 program in Minnesota. This means we offer more clinical trials than any other children’s hospital in the state. New treatments are discovered and applied here first, often becoming national standards of care.
Current open trials include one to help determine the best treatment for a child’s neuroblastoma based on genetic material and another to study the survivorship of patients with high risk or relapsed solid tumors. Ask your child’s physician about participating in a clinical trial.
